Risk group | Features | Percent | Recommended therapy | Projected five-year event-free survival |
Low | ALL of the following:
| 15% | Conventional antimetabolite-based therapy | >95% |
Average | EITHER of the following:
| 36% | Intensified antimetabolite therapy | 90 to 95% |
High | ANY of the following:
| 25% | Intensive multiagent chemotherapy | 88 to 90% |
Very high | ANY of the following:
| 24% | Consider allogeneic hematopoietic cell transplantation in first remission Allogeneic transplant not recommended for infants | <80% |
Special groups | T cell ALL | Intensive multiagent chemotherapy | 66 to 80%[1,2]
| |
Philadelphia chromosome | Intensive multiagent chemotherapy containing a BCR-ABL tyrosine kinase inhibitor | 70%[3] |
Do you want to add Medilib to your home screen?